Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab Safety Study in Advanced Ovarian Cancer
NCT00377429Phase 2Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Sep 2006
- Primary completion
- Feb 2008
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in ovarian cancer, sponsored by Neovii Pharmaceuticals. Started Sep 2006; status: completed.
02
Drugs
catumaxomab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00377429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377429.